Format

Send to

Choose Destination
Neurochem Int. 2019 Mar;124:62-67. doi: 10.1016/j.neuint.2018.12.013. Epub 2018 Dec 22.

Chitinase-3-like protein 1 may be a potential biomarker in patients with drug-resistant epilepsy.

Author information

1
Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
2
Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. Electronic address: luojingguiwu@163.com.
3
Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. Electronic address: wangweiguiwu@163.com.

Abstract

The mechanisms of the pathogenesis of epilepsy remain unclear. Recent research shows that the inflammatory process occurring in the brain may be a common and critical mechanism of seizures. Chitinase-3-like protein 1 (CHI3L1 or YKL-40) is a newly discovered inflammatory factor. We aimed to evaluate the role of YKL-40 as a biomarker for epilepsy. 124 subjects were classified as control group (n = 23), new-diagnosis epilepsy group (NDE, n = 34), drug responsive epilepsy group (DPE, n = 37), and drug-resistant epilepsy group (DRE, n = 30) YKL-40 was measured by ELISA in serum and cerebrospinal fluid (CSF). The concentrations of serum and CSF YKL-40 and its diagnostic accuracy for epilepsy were analysed. Patients with DRE had higher concentrations of YKL-40 in serum and CSF, while patients with NDE and DPE had increased YKL-40 levels in CSF but not serum in comparison with control. Moreover, serum and CSF YKL-40 provide high diagnostic accuracy for DRE. YKL-40 may play a possible pathogenic role in epilepsy. YKL-40 may represent a potential biomarker of brain inflammation in patients with DRE.

KEYWORDS:

Biomarker; Chitinase-3-like protein 1; Drug-resistant epilepsy

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center